CD47 and neoplasm: Numerous studies over the past few years, predominantly led by Weissman and colleagues, showed that blocking CD47 using anti-CD47 monoclonal antibodies allows for increased phagocytosis of cancer cells in vitro and decreased tumor burden in vivo [162, 163, 165, 166].